208 related articles for article (PubMed ID: 30185083)
1. Effectiveness and impact of the 10-valent pneumococcal conjugate vaccine, PHiD-CV: review of clinical trials and post-marketing experience.
Mrkvan T; Pelton SI; Ruiz-Guiñazú J; Palmu AA; Borys D
Expert Rev Vaccines; 2018 Sep; 17(9):797-818. PubMed ID: 30185083
[TBL] [Abstract][Full Text] [Related]
2. Impact of the introduction of the pneumococcal conjugate vaccine in the Brazilian routine childhood national immunization program.
Moreira M; Cintra O; Harriague J; Hausdorff WP; Hoet B
Vaccine; 2016 May; 34(25):2766-78. PubMed ID: 27113162
[TBL] [Abstract][Full Text] [Related]
3. Pneumococcal conjugated vaccine: PHiD-CV.
Dinleyici EC; Yargic ZA
Expert Rev Anti Infect Ther; 2009 Nov; 7(9):1063-74. PubMed ID: 19883326
[TBL] [Abstract][Full Text] [Related]
4. Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage.
Prymula R; Hanovcova I; Splino M; Kriz P; Motlova J; Lebedova V; Lommel P; Kaliskova E; Pascal T; Borys D; Schuerman L
Vaccine; 2011 Feb; 29(10):1959-67. PubMed ID: 21215830
[TBL] [Abstract][Full Text] [Related]
5. Direct and Indirect Effectiveness of the 10-Valent Pneumococcal Conjugate Vaccine Against Carriage in a Cluster Randomized Trial.
Palmu AA; Toropainen M; Kaijalainen T; Siira L; Lahdenkari M; Nieminen H; Syrjänen RK; Kilpi TM; Jokinen J
Pediatr Infect Dis J; 2017 Dec; 36(12):1193-1200. PubMed ID: 28737627
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants: A phase 2, randomized, controlled, observer-blind study.
Odutola A; Ota MOC; Antonio M; Ogundare EO; Saidu Y; Foster-Nyarko E; Owiafe PK; Ceesay F; Worwui A; Idoko OT; Owolabi O; Bojang A; Jarju S; Drammeh I; Kampmann B; Greenwood BM; Alderson M; Traskine M; Devos N; Schoonbroodt S; Swinnen K; Verlant V; Dobbelaere K; Borys D
Vaccine; 2017 May; 35(19):2531-2542. PubMed ID: 28389097
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity, impact on carriage and reactogenicity of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Kenyan children aged 1-4 years: a randomized controlled trial.
Hammitt LL; Ojal J; Bashraheil M; Morpeth SC; Karani A; Habib A; Borys D; Goldblatt D; Scott JA
PLoS One; 2014; 9(1):e85459. PubMed ID: 24465570
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine against acute otitis media and nasopharyngeal carriage in Panamanian children - A randomized controlled trial.
Sáez-Llorens X; Rowley S; Wong D; Rodríguez M; Calvo A; Troitiño M; Salas A; Vega V; Castrejón MM; Lommel P; Pascal TG; Hausdorff WP; Borys D; Ruiz-Guiñazú J; Ortega-Barría E; Yarzabal JP; Schuerman L
Hum Vaccin Immunother; 2017 Jun; 13(6):1-16. PubMed ID: 28368738
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial.
Tregnaghi MW; Sáez-Llorens X; López P; Abate H; Smith E; Pósleman A; Calvo A; Wong D; Cortes-Barbosa C; Ceballos A; Tregnaghi M; Sierra A; Rodriguez M; Troitiño M; Carabajal C; Falaschi A; Leandro A; Castrejón MM; Lepetic A; Lommel P; Hausdorff WP; Borys D; Ruiz Guiñazú J; Ortega-Barría E; Yarzábal JP; Schuerman L;
PLoS Med; 2014 Jun; 11(6):e1001657. PubMed ID: 24892763
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPa vaccine in Japanese children: A randomized, controlled study.
Iwata S; Kawamura N; Kuroki H; Tokoeda Y; Miyazu M; Iwai A; Oishi T; Sato T; Suyama A; François N; Shafi F; Ruiz-Guiñazú J; Borys D
Hum Vaccin Immunother; 2015; 11(4):826-37. PubMed ID: 25830489
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D-Conjugated Vaccine (PHiD-CV) Against Carriage and Acute Otitis Media-A Double-Blind Randomized Clinical Trial in Finland.
Vesikari T; Forsten A; Seppä I; Kaijalainen T; Puumalainen T; Soininen A; Traskine M; Lommel P; Schoonbroodt S; Hezareh M; Moreira M; Borys D; Schuerman L
J Pediatric Infect Dis Soc; 2016 Sep; 5(3):237-248. PubMed ID: 27125273
[TBL] [Abstract][Full Text] [Related]
12. Bacterial nasopharyngeal carriage following infant immunization with pneumococcal conjugate vaccines according to a 2+1 schedule in children in South Africa: an exploratory analysis of two clinical trials.
Nunes MC; Moreira M; Koen A; van Niekerk N; Jose L; Cutland CL; François N; Schoonbroodt S; Ruiz-Guiñazú J; Yarzabal JP; Borys D; Schuerman L; Madhi SA
Expert Rev Vaccines; 2020 Dec; 19(12):1177-1189. PubMed ID: 33245004
[No Abstract] [Full Text] [Related]
13. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.
Bermal N; Szenborn L; Chrobot A; Alberto E; Lommel P; Gatchalian S; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S89-96. PubMed ID: 19325451
[TBL] [Abstract][Full Text] [Related]
14. 10-Valent pneumococcal non-typeable haemophilus influenzae protein D-conjugate vaccine: a review in infants and children.
Plosker GL
Paediatr Drugs; 2014 Oct; 16(5):425-44. PubMed ID: 25192686
[TBL] [Abstract][Full Text] [Related]
15. A cost-effectiveness analysis of PHiD-CV compared to PCV13 in a national immunization program setting in Tunisia.
Lagoubi Y; Sfar MT; Gomez JA
Hum Vaccin Immunother; 2022 Nov; 18(5):2079305. PubMed ID: 35703731
[TBL] [Abstract][Full Text] [Related]
16. Immunological memory and nasopharyngeal carriage in 4-year-old children previously primed and boosted with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) with or without concomitant prophylactic paracetamol.
Prymula R; Habib A; François N; Borys D; Schuerman L
Vaccine; 2013 Apr; 31(16):2080-8. PubMed ID: 23391599
[TBL] [Abstract][Full Text] [Related]
17. Effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae among children in São Paulo, Brazil.
Brandileone MC; Zanella RC; Almeida SCG; Brandao AP; Ribeiro AF; Carvalhanas TMP; Sato H; Andrade AL; Verani JR;
Vaccine; 2016 Nov; 34(46):5604-5611. PubMed ID: 27692770
[TBL] [Abstract][Full Text] [Related]
18. Immunologic non-inferiority and safety of the investigational pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) 4-dose vial presentation compared to the licensed PHiD-CV 1-dose vial presentation in infants: A phase III randomized study.
Zaman K; Zaman SF; Zaman F; Aziz A; Faisal SB; Traskine M; Habib MA; Ruiz-Guiñazú J; Borys D
Vaccine; 2018 Jan; 36(5):698-706. PubMed ID: 29277353
[TBL] [Abstract][Full Text] [Related]
19. Streptococcus pneumoniae serotype 19A: worldwide epidemiology.
Isturiz R; Sings HL; Hilton B; Arguedas A; Reinert RR; Jodar L
Expert Rev Vaccines; 2017 Oct; 16(10):1007-1027. PubMed ID: 28783380
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
